A Phase 2 interventional study of Pomalidomide and Prednisone in Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia and Myelofibrosis, sponsored by Celgene. Completed at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 1 of them phase 3. Primary Myelofibrosis · Bristol-Myers Squibb.
Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 1st registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →1 of the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 92 across the 10 interventional studies, 150 across the 3 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
Participants received study treatment in the Double Blind Treatment Phase for up to 12 cycles (336 days; 12 cycles of 28 days each). Participants who completed the Double-Blind Treatment Phase were unblinded and, if receiving pomalidomide and determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, could have continued on their current dose of pomalidomide until disease progression. Participants receiving placebo were discontinued from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have adequate organ function as demonstrated by the following ≤ 14 days prior to starting study drug:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants were discontinued from the study.
Drug: Prednisone · Drug: Placebo to pomalidomide
Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase. After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.
Drug: Pomalidomide · Drug: Placebo to prednisone
Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.
Drug: Pomalidomide · Drug: Prednisone
Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase. After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal.
Drug: Pomalidomide · Drug: Prednisone
Also known as: CC-4047, Pomalyst
Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
Matching pomalidomide placebo tablets
Matching prednisone placebo tablets
Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment
A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.
Time frame: Up to 168 days
Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment
A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.
Time frame: Up to 336 days
Time to the First Clinical Response
The time to the first clinical response achieved within 168 days after the first study drug dosing date was calculated for participants who achieved a clinical response as: Start date of the first clinical response - the first study drug date +1. A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable.
Time frame: Up to 168 days
Duration of First Clinical Response
For RBC-transfusion-dependent patients, duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the date of the first RBC-transfusion administrated at or more than 56 days after the response started. For patients who did not receive a subsequent transfusion after the response started, the end date of response was censored at the day of last hemoglobin assessment. For RBC-transfusion-independent patients, the duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the earlier of the date of a hemoglobin increase of \< 2.0 g/dL and the date of a RBC transfusion at ≥ 56 days after the response started. For patients whose hemoglobin measurements were always ≥ 2.0 g/dL and never received a RBC transfusion after response started, the end date of the response was censored at the date of last hemoglobin measurement. Kaplan-Meier methodology was used.
Time frame: Up to 40 months
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Subscale and Total Scores
The FACT-An comprises the four subscales of the 27-item FACT-General Scale (FACT-G), Physical Well-being, Social/Family Well-being, Emotion Well-being, Functional Well-Being, and the Additional Concerns Anemia subscale. Questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life. * Physical Well-being consists of 7 questions, the subscale score ranges from 0-28; * Social/Family Well-being consists of 7 questions, the subscale score ranges from 0-28; * Emotion Well-being consists of 6 questions, the subscale score ranges from 0-24; * Functional Well-Being consists of 7 questions, the subscale score ranges from 0-28; * Anemia subscale consists of 20 questions, the subscale score ranges from 0-80; * Total FACT-An score ranges from 0-188.
Time frame: Baseline and Cycle 6 (168 days).
Change From Baseline in Hemoglobin Concentration for Responders
Change from Baseline in hemoglobin for participants with a clinical response within the first 6 cycles of treatment.
Time frame: Baseline, Cycle 6 (168 days)
Change From Baseline in Hemoglobin Concentration for Non-Responders
Change from Baseline in hemoglobin for participants without a clinical response within the first 6 cycles of treatment.
Time frame: Baseline, Cycle 6 (168 days)
Change From Baseline in Likert Abdominal Pain Scale
Participants rated abdominal discomfort or pain over the previous week on a scale from zero to ten, where zero is no discomfort or pain and ten is the worst pain imaginable.
Time frame: Baseline and Cycle 6 (168 days)
Percentage of Participants With Clinical Response by Baseline JAK2 Assessment
Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.
Time frame: Up to 336 days
Number of Participants With Adverse Events (AEs)
A serious AE (SAE) was defined as any AE which resulted in death or was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or constituted an important medical event (events that may have jeopardized the patient or required intervention to prevent one of the outcomes listed above). The severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) or according to the following scale: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Death. The Investigator determined the relationship between study drug and the occurrence of an AE as "Not Related" or "Related" (since the study was double-blinded, a patient receiving only prednisone could have an AE that was judged as related to pomalidomide, and vice-versa).
Time frame: From date of the first dose of the study drug until discontinuation or the data cut-off date (up to approximately 45 months).
| Milestone | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Started | 22 | 22 | 22 | 22 |
| Treated | 22 | 22 | 19 | 22 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 22 | 22 | 22 | 22 |
| Withdrew: Other | 4 | 3 | 6 | 4 |
| Withdrew: Adverse event | 5 | 8 | 4 | 2 |
| Withdrew: Lack of efficacy | 6 | 6 | 7 | 9 |
| Withdrew: Withdrawal by subject | 3 | 3 | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Death | 2 | 1 | 2 | 0 |
| Withdrew: Missing | 2 | 0 | 0 | 2 |
| Withdrew: 1 participant received commercial drug | 0 | 1 | 0 | 0 |
A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.
| percentage of participants | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment | 55.0 (31.53 to 76.94) | 23.5 (6.81 to 49.90) | 21.1 (6.05 to 45.57) | 47.6 (25.71 to 70.22) |
A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable. Participants who discontinued the study early without achieving clinical response were counted as non-responders.
| percentage of participants | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Percentage of Participants With a Clinical Response Within the First 12 Cycles of Treatment | 50.0 (28.22 to 71.78) | 18.2 (5.19 to 40.28) | 18.2 (5.19 to 40.28) | 45.5 (24.39 to 67.79) |
The time to the first clinical response achieved within 168 days after the first study drug dosing date was calculated for participants who achieved a clinical response as: Start date of the first clinical response - the first study drug date +1. A clinical responder was defined as either: 1. A baseline red blood cell (RBC)-transfusion-dependent participant with a ≥ 56 consecutive day RBC transfusion-free period after the first dose of study drug, or 2. A baseline RBC-transfusion-independent participant with an increase in hemoglobin of 2.0 g/dL or more from baseline for ≥ 56 consecutive days in the absence of RBC transfusions, or 3. A participant with either a ≥ 50% reduction in palpable splenomegaly of a spleen that was ≥ 10 cm at baseline or a spleen that was palpable at \> 5 cm and became not palpable.
| weeks | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Time to the First Clinical Response | 0.3 (0.1 to 15.6) | 8.0 (2.6 to 17.3) | 10.1 (0.1 to 20.0) | 1.2 (0.1 to 16.6) |
For RBC-transfusion-dependent patients, duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the date of the first RBC-transfusion administrated at or more than 56 days after the response started. For patients who did not receive a subsequent transfusion after the response started, the end date of response was censored at the day of last hemoglobin assessment. For RBC-transfusion-independent patients, the duration of response was calculated as the last day of response - first day of response +1, where the last day of response was the earlier of the date of a hemoglobin increase of \< 2.0 g/dL and the date of a RBC transfusion at ≥ 56 days after the response started. For patients whose hemoglobin measurements were always ≥ 2.0 g/dL and never received a RBC transfusion after response started, the end date of the response was censored at the date of last hemoglobin measurement. Kaplan-Meier methodology was used.
| months | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Duration of First Clinical Response | 3.7 (3.0 to 6.6) | NA (4.7 to NA) | 6.0 (2.3 to 9.8) | 10.6 (2.8 to 16.1) |
The FACT-An comprises the four subscales of the 27-item FACT-General Scale (FACT-G), Physical Well-being, Social/Family Well-being, Emotion Well-being, Functional Well-Being, and the Additional Concerns Anemia subscale. Questions are rated on a scale from 0 to 4, where higher scores indicate more impact on quality of life. * Physical Well-being consists of 7 questions, the subscale score ranges from 0-28; * Social/Family Well-being consists of 7 questions, the subscale score ranges from 0-28; * Emotion Well-being consists of 6 questions, the subscale score ranges from 0-24; * Functional Well-Being consists of 7 questions, the subscale score ranges from 0-28; * Anemia subscale consists of 20 questions, the subscale score ranges from 0-80; * Total FACT-An score ranges from 0-188.
| units on a scale | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Physical Well-Being subscale | 0.6 ± 1.50 | 0.4 ± 6.42 | 5.3 ± 4.04 | 2.3 ± 2.26 |
| Social/Family Well-Being subscale | 1.9 ± 3.08 | -1.9 ± 2.59 | 1.7 ± 3.79 | 0.9 ± 6.84 |
| Emotional Well-Being subscale | 1.3 ± 3.32 | 0.0 ± 4.76 | -0.3 ± 0.58 | 1.7 ± 3.47 |
| Functional Well-Being subscale | 0.9 ± 4.14 | -2.1 ± 8.99 | 2.7 ± 3.06 | 2.5 ± 6.50 |
| Anemia subscale | 1.2 ± 9.47 | 2.3 ± 21.34 | 19.3 ± 18.93 | 5.8 ± 8.85 |
| Total FACT-An score | 2.3 ± 12.42 | 1.6 ± 36.51 | 27.3 ± 25.74 | 11.4 ± 13.51 |
Change from Baseline in hemoglobin for participants with a clinical response within the first 6 cycles of treatment.
| g/dL | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin Concentration for Responders | 1.4 (-0.5 to 4.1) | 2.0 (0.7 to 3.2) | — | -0.1 (-1.9 to 3.9) |
Change from Baseline in hemoglobin for participants without a clinical response within the first 6 cycles of treatment.
| g/dL | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin Concentration for Non-Responders | 1.2 (-0.2 to 2.7) | 0.1 (-0.8 to 1.3) | -0.8 (-2.0 to 1.9) | 0.5 (-0.3 to 1.0) |
Participants rated abdominal discomfort or pain over the previous week on a scale from zero to ten, where zero is no discomfort or pain and ten is the worst pain imaginable.
| units on a scale | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Change From Baseline in Likert Abdominal Pain Scale | 0.3 ± 1.83 | -1.0 ± 3.11 | 0.3 ± 1.15 | -0.1 ± 1.68 |
Percentage of participants who achieved a clinical response, presented by participants with positive and negative janus kinase 2 (JAK2) V617F mutation results at Baseline.
| percentage of participants | Prednisone, Positive JAK2 | Pomalidomide 2 mg, PositiveJAK2 | Pomalidomide 2 mg + Prednisone, Positive JAK2 | Pomalidomide 0.5 mg + Prednisone, Positive JAK2 | Prednisone, Negative JAK2 | Pomalidomide 2 mg, Negative JAK2 | Pomalidomide 2 mg + Prednisone, Negative JAK2 | Pomalidomide 0.5 mg + Prednisone, Negative JAK2 |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Clinical Response by Baseline JAK2 Assessment | 46.2 | 27.3 | 30.0 | 66.7 | 50.0 | 28.6 | 12.5 | 25.0 |
A serious AE (SAE) was defined as any AE which resulted in death or was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or constituted an important medical event (events that may have jeopardized the patient or required intervention to prevent one of the outcomes listed above). The severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) or according to the following scale: Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Death. The Investigator determined the relationship between study drug and the occurrence of an AE as "Not Related" or "Related" (since the study was double-blinded, a patient receiving only prednisone could have an AE that was judged as related to pomalidomide, and vice-versa).
| participants | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| At least one AE | 20 | 21 | 18 | 21 |
| At least one AE related to pomalidomide | 15 | 17 | 16 | 15 |
| At least one AE related to prednisone | 10 | 10 | 11 | 5 |
| At least one Grade 3-4 AE | 10 | 14 | 13 | 15 |
| At least one Grade 3-4 AE related to pomalidomide | 6 | 7 | 11 | 6 |
| At least one Grade 3-4 AE related to prednisone | 5 | 2 | 6 | 3 |
| At least one SAE | 6 | 10 | 11 | 8 |
| At least one SAE related to pomalidomide | 4 | 6 | 8 | 3 |
| At least one SAE related to prednisone | 4 | 3 | 5 | 3 |
| AE leading to discontinuation of pomalidomide | 7 | 11 | 5 | 6 |
| AE leading to discontinuation of prednisone | 5 | 7 | 2 | 1 |
| AE leading to a dose reduction of pomalidomide | 0 | 2 | 1 | 1 |
| AE leading to a dose interruption of pomalidomide | 5 | 9 | 9 | 7 |
| AE leading to a dose interruption of prednisone | 2 | 8 | 6 | 3 |
Collected over From the first dose of the study drug through to 30 days after the last dose; up to the data cut-off date of 18 December 2013; up to 81 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prednisone | — | 6/22 (27.3%) | 20/22 (90.9%) |
| Pomalidomide 2 mg | — | 10/22 (45.5%) | 20/22 (90.9%) |
| Pomalidomide 2 mg + Prednisone | — | 11/19 (57.9%) | 17/19 (89.5%) |
| Pomalidomide 0.5 mg + Prednisone | — | 9/22 (40.9%) | 21/22 (95.5%) |
| Event | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/22 | 3/22 | 3/19 | 2/22 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/22 | 2/22 | 1/19 | 0/22 |
| AnaemiaBlood and lymphatic system disorders | 0/22 | 1/22 | 1/19 | 2/22 |
| PyrexiaGeneral disorders | 0/22 | 2/22 | 0/19 | 0/22 |
| Renal Failure AcuteRenal and urinary disorders | 0/22 | 2/22 | 1/19 | 0/22 |
| BradycardiaCardiac disorders | 0/22 | 0/22 | 1/19 | 0/22 |
| Lung Infection PseudomonalInfections and infestations | 0/22 | 0/22 | 1/19 | 0/22 |
| Respiratory Tract InfectionInfections and infestations | 0/22 | 0/22 | 1/19 | 0/22 |
| Urinary Tract Infection EnterococcalInfections and infestations | 0/22 | 0/22 | 1/19 | 0/22 |
| DehydrationMetabolism and nutrition disorders | 1/22 | 0/22 | 1/19 | 0/22 |
| Event | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone |
|---|---|---|---|---|
| Oedema PeripheralGeneral disorders | 6/22 | 8/22 | 10/19 | 10/22 |
| DiarrhoeaGastrointestinal disorders | 5/22 | 6/22 | 7/19 | 1/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/22 | 6/22 | 4/19 | 8/22 |
| DizzinessNervous system disorders | 4/22 | 2/22 | 6/19 | 8/22 |
| RashSkin and subcutaneous tissue disorders | 1/22 | 8/22 | 3/19 | 3/22 |
| FatigueGeneral disorders | 6/22 | 2/22 | 6/19 | 7/22 |
| PyrexiaGeneral disorders | 5/22 | 7/22 | 4/19 | 6/22 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/22 | 7/22 | 3/19 | 6/22 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 3/22 | 1/22 | 6/19 | 5/22 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/22 | 2/22 | 5/19 | 3/22 |
| Age, Continuous(years) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Median | 66.0 (44.0 to 80.0) | 68.0 (50.0 to 83.0) | 67.5 (36.0 to 82.0) | 69.5 (43.0 to 86.0) | 67.5 (36.0 to 86.0) |
| Sex: Female, Male(Participants) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Female | 8 | 5 | 7 | 9 | 29 |
| Male | 14 | 17 | 15 | 13 | 59 |
| Race/Ethnicity, Customized(participants) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| White | 21 | 22 | 21 | 22 | 86 |
| Black | 0 | 0 | 1 | 0 | 1 |
| Hispanic | 1 | 0 | 0 | 0 | 1 |
| Janus kinase 2 (JAK2) Mutation(participants) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Negative | 6 | 7 | 8 | 8 | 29 |
| Positive | 13 | 11 | 10 | 9 | 43 |
| Missing | 3 | 4 | 4 | 5 | 16 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Grade 0 | 12 | 11 | 6 | 14 | 43 |
| Grade 1 | 8 | 9 | 10 | 6 | 33 |
| Grade 2 | 2 | 2 | 5 | 2 | 11 |
| Missing | 0 | 0 | 1 | 0 | 1 |
| Myelofibrosis with myeloid metaplasia Subtype(participants) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Agnogenic Myeloid Metaplasia (AMM) | 16 | 16 | 16 | 13 | 61 |
| Postpolycythemic Myeloid Metaplasia (PPMM) | 3 | 4 | 4 | 2 | 13 |
| Postthromocythemic Myeloid Metaplasia (PTMM) | 3 | 2 | 2 | 7 | 14 |
| Time Since Myelofibrosis Diagnosis(years) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Median | 1.5 (0.0 to 14.3) | 0.6 (0.0 to 6.3) | 1.1 (0.0 to 13.0) | 1.7 (0.0 to 10.9) | 1.1 (0.0 to 14.3) |
| Red Blood Cell (RBC) Transfusion Dependence(participants) | Prednisone | Pomalidomide 2 mg | Pomalidomide 2 mg + Prednisone | Pomalidomide 0.5 mg + Prednisone | Total |
|---|---|---|---|---|---|
| Yes | 12 | 10 | 9 | 12 | 43 |
| No | 10 | 12 | 13 | 10 | 45 |
1 further baseline measures are reported on the registry.
Ran from Apr 2007 to primary completion in May 2009, 25 months.
Results were first posted in Oct 2013, 4 years 5 months after primary completion. A results delay was requested in Jan 2011.
Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 25 months is below that.
Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pomalidomide · Prednisone